Efficacy and safety of salvianolate injection on non-ST-segment elevation acute coronary syndrome patients with percutaneous coronary intervention

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016992

Enrollment

Unknown

Registered

2018-07-06

Start date

2016-10-08

Completion date

Unknown

Last updated

2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSTEMI-ACS

Interventions

Experimental group:Salvianolate injection

Control group:Normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-85 years old male or female; 2. NSTEMI-ACS includes: unstable angina, non-ST-segment elevation myocardial infarction (although the myocardial marker cTnT increased before PCI, but in a steady or decreasing trend); 3. In line with PCI treatment indications, need to receive PCI treatment.

Exclusion criteria

Exclusion criteria: 1. Acute ST-segment elevation myocardial infarction; 2. High-risk acute non-ST-segment elevation myocardial infarction, need urgent coronary angiography; 3. Refractory myocardial ischemia or severe arrhythmia; 4. History of severe renal or hepatic insufficiency; 5. Allergic to salvianolate polyphenolate; 6. Pregnancy or lactation; 7. Unwilling or unable to sign informed consent.

Design outcomes

Primary

Measure	Time frame
MACE;	—

Secondary

Measure	Time frame
cTnT;CK-MB;	—

Countries

China

Contacts

Public ContactShen Wei

Huashan Hospital Affiliated to Fudan University

drshenwei@aliyun.com+86 21 52887065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026